Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry association warns of Cancer Drugs Fund's potential to worsen regional variations in access to cancer treatments.
Advertisement

Related Content

Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails
NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits
UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits
UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

Topics

Advertisement
UsernamePublicRestriction

Register

PS071713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel